BIIB Q3 2017 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q3 2017 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.1B+4.1% YoY

Gross Profit

$2.7B88.0% margin

Operating Income

$1.7B53.7% margin

Net Income

$1.2B39.8% margin

EPS (Diluted)

$5.79

QoQ Revenue Growth

-0.0%

Cash Flow

Operating Cash Flow

$1.6B

Free Cash Flow

$1.3B

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$23.1B

Total Liabilities

$10.2B

Stockholders' Equity

$12.9B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.1B	$3.0B	+4.1%
Gross Profit	$2.7B	$2.5B	+6.7%
Operating Income	$1.7B	$1.4B	+16.0%
Net Income	$1.2B	$1.0B	+18.7%

Revenue Segments

Hemophilia Products

$74M100%